We study optimal secondary prevention after myocardial infarction, e.g., use of beta blockers, cholesterol lowering medications, and elucidate mechanisms linked to myocardial protection.
In addition, we have several projects focusing on cardiovascular (CV) biomarkers, i.e., both known biomarkers used for early diagnostication of myocardial infarction and identification of new biomarkers.
We also study the deleterious effects of anabolic steroids on the cardiovascular system. The efficiency and safety of anticoagulants is being evaluated by accessing data from Norwegian and international registries.
Finally, we have ongoing projects assessing optimal treatment of myocardial infarction, incidence of heart failure in Norway, and prevalence and treatment of atrial fibrillation in Scandinavia. In the MINOCA project, we study the optimal examinations of these patients. The multinational EXHAUSTION will produce more knowledge about the association between climate and CVD.
We also study patients with autoimmune joint diseases and look at inflammatory and cardiac markers in RA patients in relation to CVD. Furthermore we are engaged in a multinational project looking at ultrasound of the carotid artery in relation to CVD.
- Raskere avklaring av akutt hjerteinfarkt på Legevakten i Oslo (OUT-ACS-studien)
- Improving the safety of oral anticoagulants
- The BETAMI trial (national trial on the use of beta blockers in myocardial infarction)
- Detecting changes in cardiac extracellular matrix – identification of novel biomarkers
- Quality of care and outcome in acute myocardial infarction - A population-based study
- Heart failure in Norway – a registry-based approach
- The role of genetic factors in acute myocardial infarction
- Use of Music therapy in Cardiac Implantable Electronic Device (CIED) lead extractions
- Hyperemesis gravidarum and cardiovascular disease
- Involved in SMINC (MINOCA Myocardial Infarction with Non-Obstructrive Coronary Arteries), EXHAUSTION (Exposure to heat and air pollution in Europe – cardiopulmonary impacts and benefits of mitigation and adaptation), PSARA (Inflammatory Disease Activity, and Bone and Cartilage Markers in Rheumatic Patients, and the PROG-IMT
- Karolinska Institutet, Stockholm
- Cleveland Clinic Foundation, Professor A. Michael Krukoff
- Université de Lorraine, Professor F. Zannad
- Uppsala Clinical Research Center, Professor Lars Wallentin
- Senter for Klinisk Hjerteforskning, OUH Ullevål
- Kåre Bønaa, NTNU
- Jarle Jortveit, Sørlandet Hospital